{
    "id": 1163,
    "fullName": "ESR1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ESR1 positive indicates the presence of the ESR1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2099,
        "geneSymbol": "ESR1",
        "terms": [
            "ESR1",
            "ER",
            "Era",
            "ESR",
            "ESRA",
            "ESTRR",
            "NR3A1"
        ]
    },
    "variant": "positive",
    "createDate": "07/27/2014",
    "updateDate": "04/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12594,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combination of Afinitor (everolimus) and Faslodex (fulvestrant) resulted in significantly improved progression-free survival compared to Faslodex (fulvestrant) monotherapy (HR=0.64, p=0.02) in estrogen-receptor positive breast cancer patients (San Antonio Breast Cancer Symposium, Dec 6, 2017, GS2-07; NCT02216786).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10465,
                    "pubMedId": null,
                    "title": "A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer",
                    "url": "http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_741"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9020,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combination of Vistusertib (AZD2014) and Faslodex (fulvestrant) did not significantly improve progression-free survival compared to Faslodex (fulvestrant) monotherapy (HR=0.87, p=0.42) in estrogen-receptor positive breast cancer patients (San Antonio Breast Cancer Symposium, Dec 6, 2017, GS2-07; NCT02216786).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2199,
                "therapyName": "Fulvestrant + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10465,
                    "pubMedId": null,
                    "title": "A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer",
                    "url": "http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_741"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6409,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, the combination of Arimidex (anastrozole) and Pictilisib (GDC-0941) resulted in improved inhibition of tumor cell proliferation in ER-positive, ERBB2 (HER2)-negative breast cancer patients compared to Arimidex (anastrozole) treatment alone, particularly in the luminal B subtype (PMID: 26976426).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4123,
                "therapyName": "Anastrozole + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5563,
                    "pubMedId": 26976426,
                    "title": "Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26976426"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4267,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cixutumumab treatment had no beneficial effects on progression-free survival and overall survival in patients with hormone receptor positive (Esr1 and/or Pgr positive) breast adenocarcinoma (PMID: 26324738).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 701,
                "therapyName": "Cixutumumab",
                "synonyms": null
            },
            "indication": {
                "id": 3458,
                "name": "breast adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4473,
                    "pubMedId": 26324738,
                    "title": "Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21140,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ERBB2 (HER2)-negative/ESR1 (ER)-positive breast cancer cell line demonstrated sensitivity to treatment with Abemaciclib (LY2835219) in xenograft models, resulting in decreased tumor volume (PMID: 27217383).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11835,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MONARCH 1) that supported FDA approval, Verzenio (abemaciclib) treatment resulted in an objective response rate of 19.7% (26/132), a clinical benefit rate of 42.4% (56/132), median progression-free survival of 6.0 months, and median overall survival of 17.7 months in patients with refractory hormone receptor positive, Erbb2 (Her2) negative metastatic breast cancer (PMID: 28533223; NCT02102490).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9866,
                    "pubMedId": 28533223,
                    "title": "MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28533223"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9010,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) resulted in decreased cell proliferation in culture in ER positive breast cancer cell lines, including cell lines that were deprived of estrogen long term and/or resistant to Afinitor (everolimus), and showed inhibition of tumor growth and tumor regression in ER positive breast cancer cell line xenograft models (PMID: 26358751).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6854,
                    "pubMedId": 26358751,
                    "title": "AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358751"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8957,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-2) that supported FDA approval, Kisqali (ribociclib) plus Femara (letrozole) as first-line therapy resulted in an 18 month progression-free survival rate of 63.0% compared to 42.2% with placebo plus Femara (letrozole), and an overall response rate of 52.7%, compared to 31.7% with placebo in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 27717303; NCT01958021).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6802,
                    "pubMedId": 27717303,
                    "title": "Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27717303"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14539,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6925,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD9496 and Ibrance (palbociclib) induced tumor regression in xenograft models of ER-positive/PR-positive/ERBB2 (HER2)-positive breast cancer, compared to tumor stasis with either agent alone (PMID: 27020862).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4294,
                "therapyName": "AZD9496 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5956,
                    "pubMedId": 27020862,
                    "title": "AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18081,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, combination of Afinitor (everolimus) and Faslodex (fulvestrant) was associated with improved survival (p<0.05) in patients with hormone receptor-positive metastatic breast cancer (PMID: 31088410).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15992,
                    "pubMedId": 31088410,
                    "title": "Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31088410"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19382,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (POSEIDON), combination of Nolvadex (tamoxifen) and Taselisib (GDC-0032) demonstrated safety, resulted in an objective response rate of 24% (6/25) in RECIST-evaluable patients with ESR1-positive metastatic breast cancer, with a median time to progression of 8 months (PMID: 31439579; NCT02301988).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 9009,
                "therapyName": "Tamoxifen + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16939,
                    "pubMedId": 31439579,
                    "title": "POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31439579"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9905,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, hormone receptor positive/ERBB2 (HER2) negative breast cancer patients treated with Abemaciclib (LY2835219) demonstrated a greater decrease in proliferation markers than treatment with Arimidex (anastrozole) (SABC 2016 Meeting, Abstract S4-06).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7752,
                    "pubMedId": null,
                    "title": "Biological effects of abemaciclib in a phase 2 neoadjuvantstudy for postmenopausal patients with HR+, HER2- breast cancer",
                    "url": "https://www.sabcs.org/Past-Meetings"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7448,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, hormone receptor positive breast cancer patients treated with Abemaciclib (LY2835219) demonstrated a disease control rate of 81% compared to hormone receptor negative breast cancer patients with a disease control rate of 33% (PMID: 27217383).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12936,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nolvadex (tamoxifen) therapy is included in guidelines for patients with ESR1-positive ductal carcinoma in situ (PMID: 31236598; ESMO.org, NCCN.org).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60074,
                "name": "ductal carcinoma in situ",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                },
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15502,
                    "pubMedId": 31236598,
                    "title": "Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31236598"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11361,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TTC-352 inhibited growth, induced apoptosis in estrogen-receptor positive breast cancer cell lines in culture, resulted in tumor regression in cell line xenograft models (PMID: 25205655).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 5960,
                "therapyName": "TTC-352",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9258,
                    "pubMedId": null,
                    "title": "Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_193693.html"
                },
                {
                    "id": 9259,
                    "pubMedId": 25205655,
                    "title": "Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25205655"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16713,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Chidamide (CS055) in combination with Aromasin (exemestane) resulted in improved progression-free survival (7.4 vs 3.7 months, HR=0.755, p=0.0336), objective response rate (18.4% vs 9.1%), and clinical benefit rate (46.7% vs 35.5%) compared to placebo in patients with hormone receptor positive, ERBB2 (HER2)-negative breast cancer patients (ESMO 2018 Congress, Oct 2018, Presidential Symposium 1; NCT02482753).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 8155,
                "therapyName": "Chidamide + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14746,
                    "pubMedId": null,
                    "title": "Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer",
                    "url": "https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Phase-III-trial-of-chidamide-a-subtype-selective-histone-deacetylase-HDAC-inhibitor-in-combination-with-exemestane-in-patients-with-ho"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6924,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9496 induced estrogen-receptor downregulation in ER-positive/PR-positive/ERBB2 (HER2)-positive breast cancer cells in culture, and inhibited tumor growth in xenograft models (PMID: 27020862).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2997,
                "therapyName": "AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5956,
                    "pubMedId": 27020862,
                    "title": "AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15370,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AZD9496 demonstrated safety and preliminary anti-tumor activity in patients with ESR1 (ER-alpha)-positive, ERBB2 (HER2)-negative breast cancer, resulting in a partial response in 1 patient and stable disease at 12 months in 8.9% (4/45) of patients (PMID: 29440181; NCT02248090).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2997,
                "therapyName": "AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13113,
                    "pubMedId": 29440181,
                    "title": "A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29440181"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7388,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD5363 and Falsodex (fulvestrant) inhibited tumor growth in a patient-derived xenograft (PDX) model of endocrine-resistant luminal breast cancer, with increased efficacy over either agent alone (PMID: 26116361).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6340,
                    "pubMedId": 26116361,
                    "title": "AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11164,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Elacestrant (RAD1901) treatment resulted in partial response in patients with ER-positive breast cancer, including those harboring ESR1 mutations (J Clin Oncol 35, 2017 (suppl; abstr 1014)).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 5890,
                "therapyName": "Elacestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9124,
                    "pubMedId": null,
                    "title": "Evaluation of RAD1901, a novel investigational, selective estrogen receptor degrader (SERD), for the treatment of ER-positive (ER+) advanced breast cancer.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_192812.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18446,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARV-471 treatment inhibited growth of an ESR1-positive breast cancer cell line in culture, and reduced tumor growth and induced regression in a cell line xenograft model (Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-18).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 8716,
                "therapyName": "ARV-471",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16183,
                    "pubMedId": null,
                    "title": "ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer",
                    "url": "https://cancerres.aacrjournals.org/content/79/4_Supplement/P5-04-18"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3653,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pipendoxifene and Ibrance (palbociclib) inhibited human estrogen receptor (ER)-positive breast cancer cell lines in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 3208,
                "therapyName": "Palbociclib + pipendoxifene",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6926,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD9496 and Vistusertib (AZD2014) induced tumor regression in xenograft models of ER-positive/PR-positive/ERBB2 (HER2)-positive breast cancer, compared to tumor stasis with either agent alone (PMID: 27020862).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4295,
                "therapyName": "AZD9496 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5956,
                    "pubMedId": 27020862,
                    "title": "AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3652,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of bazedoxifene and Ibrance (palbociclib) inhibited growth of human estrogen receptor (ESR1)-positive breast cancer cell lines in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2738,
                "therapyName": "Bazedoxifene + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12100,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR439859 inhibited Esr1 signaling and proliferation of Esr1-positive breast cancer cell lines in culture, and resulted in tumor regression in patient-derived xenograft models (Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-05).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 6293,
                "therapyName": "SAR439859",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10042,
                    "pubMedId": null,
                    "title": "Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/77/4_Supplement/P3-04-05"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16449,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, H3B-5942 inhibited tumor growth in ESR1 (ER alpha)-positive breast cancer patient-derived xenograft (PDX) models (PMID: 29991605).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 8021,
                "therapyName": "H3B-5942",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14484,
                    "pubMedId": 29991605,
                    "title": "Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29991605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13885,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ATAC) that supported FDA approval, Arimidex (anastrozole) treatment resulted in prolonged disease-free survival (HR=0.87, p=0.01) and time-to-recurrence (HR=0.79, p=0.0005), and decreased distant metastases (HR=0.86, p=0.04) and contralateral breast cancers (42% reduction, p=0.01) compared to Nolvadex (tamoxifen) in patients with hormone receptor-positive breast cancer (PMID: 15639680).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 633,
                "therapyName": "Anastrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11329,
                    "pubMedId": 15639680,
                    "title": "Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15639680"
                },
                {
                    "id": 15551,
                    "pubMedId": null,
                    "title": "Arimidex (anastrozole) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020541"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11906,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T48 treatment reduced Esr1 protein expression, resulting in tumor growth inhibition in animal models of Esr1-positive breast cancer resistant to tamoxifen and aromatase inhibitors (Cancer Res 2017;77(13 Suppl):Abstract nr 5641).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 6206,
                "therapyName": "G1T48",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9895,
                    "pubMedId": null,
                    "title": "Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5641.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2171,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 83% (5/6) of patients with estrogen receptor positive breast cancer that developed resistance to long term hormone therapy responded to Ethinylestradiol, demonstrating decreased expression of the estrogen receptor and inhibition of cell growth (PMID: 25774336).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2661,
                "therapyName": "Ethinylestradiol",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2700,
                    "pubMedId": 25774336,
                    "title": "Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25774336"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9021,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Vistusertib (AZD2014) and Nolvadex (tamoxifen) demonstrated decreased tumor volume similar to that of AZD2014 alone in ER-positive breast cancer cell line xenograft models insensitive to Nolvadex (tamoxifen) (PMID: 26358751).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4863,
                "therapyName": "Tamoxifen + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6854,
                    "pubMedId": 26358751,
                    "title": "AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358751"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14541,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONALEESA-7) that supported FDA approval, Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (Femara (letrozole) or Arimidex (anastrozole)) resulted in significantly improved median progression-free survival (23.8 vs 13.0 months, HR=0.55, p<0.0001) compared to placebo in premenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (PMID: 29804902; NCT02278120).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 7166,
                "therapyName": "Anastrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11737,
                    "pubMedId": 29804902,
                    "title": "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29804902"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12829,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (BOLERO-2), estrogen-receptor (ER)-positive breast cancer patients harboring neither ESR1 D538G or ESR1 Y527S mutations demonstrated a greater progression-free survival when treated with a combination of Aromasin (exemestane) and Afinitor (everolimus) versus Aromasin (exemestane) without Afinitor (everolimus) (8.5 vs 3.9 months) (PMID: 26681738).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4594,
                    "pubMedId": 26681738,
                    "title": "ESR1 Mutations Prevalent in Some Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26681738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14537,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (MONALEESA-3) trial that supported FDA approval, Faslodex (fulvestrant) in combination with Kisqali (ribociclib) resulted in significantly improved median progression-free survival (20.5 vs 12.8 months, HR=0.593, p<0.001) compared to Faslodex (fulvestrant) plus placebo in postmenopausal women with hormone receptor-positive, Erbb2 (Her2)-negative, advanced breast cancer (PMID: 29860922; NCT02422615).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2316,
                "therapyName": "Fulvestrant + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11736,
                    "pubMedId": 29860922,
                    "title": "Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860922"
                },
                {
                    "id": 15548,
                    "pubMedId": null,
                    "title": "Kisqali (ribociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12830,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-3) that supported FDA approval, the combination of Faslodex (fulvestrant) with Ibrance (palbociclib) resulted in an improved progression-free survival of 9.5 months, compared to 4.6 months with Faslodex (fulvestrant) plus placebo in ERBB2 (HER2) negative, ESR1 (ER)-positive breast cancer patients (PMID: 26947331, PMID: 27407089; NCT01942135).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6771,
                    "pubMedId": 27407089,
                    "title": "FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27407089"
                },
                {
                    "id": 10765,
                    "pubMedId": 26947331,
                    "title": "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26947331"
                },
                {
                    "id": 15541,
                    "pubMedId": null,
                    "title": "Ibrance (palbociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5895,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ODM-207 treatment resulted in decreased ER alpha signaling, inhibited proliferation of ER-positive breast cancer cell lines in culture, and suppressed tumor growth in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #4649).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 3974,
                "therapyName": "ODM-207",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5186,
                    "pubMedId": null,
                    "title": "ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=177af784-a1f1-406c-9aa8-67b47302d29b&cKey=a3591182-1c63-4601-8452-da8fc4cf389d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9906,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Abemaciclib (LY2835219) and Arimidex (anastrozole) demonstrated a greater decrease in proliferation markers than treatment with Arimidex (anastrozole) alone in hormone receptor positive/ERBB2 (HER2) negative breast cancer patients (SABC 2016 Meeting, Abstract S4-06).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2255,
                "therapyName": "Abemaciclib + Anastrozole",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7752,
                    "pubMedId": null,
                    "title": "Biological effects of abemaciclib in a phase 2 neoadjuvantstudy for postmenopausal patients with HR+, HER2- breast cancer",
                    "url": "https://www.sabcs.org/Past-Meetings"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6649,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with MK2206 in combination with Arimidex (anastrozole) resulted in a clinical benefit rate of 54% (7/13) in patients with estrogen receptor (ER)-positive, ERBB2 (HER2)-negative breast cancer (PMID: 26783290).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4188,
                "therapyName": "Anastrozole + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5720,
                    "pubMedId": 26783290,
                    "title": "A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26783290"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8857,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, the combination of Faslodex (fulvestrant) with Ibrance (palbociclib) compared to Faslodex (fulvestrant) plus placebo in ERBB2 (HER2) negative-ER-positive breast cancer patients resulted in a greater progression free survival (9.5 vs 4.6 mo) (PMID: 27407089).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6771,
                    "pubMedId": 27407089,
                    "title": "FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27407089"
                },
                {
                    "id": 15541,
                    "pubMedId": null,
                    "title": "Ibrance (palbociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3651,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) and Ibrance (palbociclib) inhibited the growth of human estrogen receptor positive breast cancer cell lines in culture (PMID: 25991817).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3924,
                    "pubMedId": 25991817,
                    "title": "Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25991817"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2522,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-2) that supported FDA approval, the addition of Ibrance (palbociclib) to treatment with Femara (letrozole) prolonged progression-free survival (24.8 mo vs 14.5 mo) in patients with ERBB2 (HER2)-negative-ER-positive breast cancer compared to Femara (letrozole) plus placebo (PMID: 27959613, PMID: 26100274; NCT01740427).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 2922,
                "therapyName": "Letrozole + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3246,
                    "pubMedId": 26100274,
                    "title": "Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26100274"
                },
                {
                    "id": 10754,
                    "pubMedId": 27959613,
                    "title": "Palbociclib and Letrozole in Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27959613"
                },
                {
                    "id": 15541,
                    "pubMedId": null,
                    "title": "Ibrance (palbociclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6657,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BOLERO-2) that supported FDA approval, the combination of Afinitor (everolimus) and Aromasin (exemestane) resulted in an improved median progression-free survival (7.8 vs 3.2 months) compared to Aromasin (exemestane) and placebo in patients with ERBB2 (HER2)-negative, hormone receptor-positive breast cancer whose disease recurred or progressed during or after nonsteroidal aromatase inhibitor therapy (PMID: 24158787; NCT00863655).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10766,
                    "pubMedId": 24158787,
                    "title": "Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24158787"
                },
                {
                    "id": 15547,
                    "pubMedId": null,
                    "title": "Afinitor (everolimus) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12383,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination of Afinitor (everolimus) and Aromasin (exemestane) improved progression-free survival compared to Aromasin (exemestane) and placebo in patients with ERBB2 (HER2)-negative, hormone-receptor-positive breast cancer regardless of their PIK3CA mutational status (PMID: 28183140).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1966,
                "therapyName": "Everolimus + Exemestane",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10362,
                    "pubMedId": 28183140,
                    "title": "Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12092,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MONARCH 2) that supported FDA approval, the combination treatment of Verzenio (abemaciclib) and Faslodex (fulvestrant) resulted in a greater median progression-free survival compared to Faslodex (fulvestrant) plus placebo (16.4 mo vs 9.3 mo, HR=0.553, p<0.0001) and improved objective response rate (48.1% vs 21.3 %) in hormone receptor-positive, ERBB2 (HER2) receptor-negative breast cancer patients (PMID: 28580882; NCT02107703).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                },
                {
                    "id": 10030,
                    "pubMedId": null,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.73.7585"
                },
                {
                    "id": 15550,
                    "pubMedId": null,
                    "title": "Verzenio (abemaciclib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4577,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, combination treatment of Buparlisib (BKM120) and Falsodex (fulvestrant) resulted in improved median progression-free survival (3.9 months) in hormone receptor-positive-ERBB2 (HER2) negative breast cancer patients compared to Falsodex (fulvestrant) plus placebo treatment alone (1.8 months) (SABCS, 2016, Abstract S4-07, PMID: 26681740).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 1546,
                "therapyName": "Buparlisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4620,
                    "pubMedId": 26681740,
                    "title": "PI3K Inhibitor Improves PFS in BELLE-2 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26681740"
                },
                {
                    "id": 7726,
                    "pubMedId": null,
                    "title": "BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2\u2013, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment",
                    "url": "https://www.sabcs.org/Past-Meetings"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6650,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with MK2206 in combination with Falsodex (fulvestrant) resulted in a clinical benefit rate of 40% (2/5) in patients with estrogen receptor (ER)-positive, ERBB2 (HER2)-negative breast cancer (PMID: 26783290).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4189,
                "therapyName": "Fulvestrant + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5720,
                    "pubMedId": 26783290,
                    "title": "A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26783290"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6927,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD9496 and AZD8835 induced tumor regression in xenograft models of ER-positive/PR-positive/ERBB2 (HER2)-positive breast cancer, compared to tumor stasis with either agent alone (PMID: 27020862).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 4293,
                "therapyName": "AZD8835 + AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5956,
                    "pubMedId": 27020862,
                    "title": "AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11913,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 and G1T48 combination treatment resulted in tumor growth inhibition in animal models of Esr1-positive breast cancer resistant to tamoxifen and aromatase inhibitors (Cancer Res 2017;77(13 Suppl):Abstract nr 5641).",
            "molecularProfile": {
                "id": 1188,
                "profileName": "ESR1 positive"
            },
            "therapy": {
                "id": 6207,
                "therapyName": "G1T38 + G1T48",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9895,
                    "pubMedId": null,
                    "title": "Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5641.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1238,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, ER-positive breast cancer patients with increased EZH2 expression showed decreased progression-free survival after treatment with Nolvadex (tamoxifen) compared to patients with lower EZH2 expression levels (PMID: 25193989).",
            "molecularProfile": {
                "id": 2349,
                "profileName": "ESR1 pos EZH2 over exp"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 701,
                    "pubMedId": 25193989,
                    "title": "High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25193989"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2388,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Telapristone inhibited cell proliferation and decreased both PR and ER signaling a PR and ER positive human breast carcinoma cell line (PMID: 21119048).",
            "molecularProfile": {
                "id": 7400,
                "profileName": "ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2820,
                "therapyName": "Telapristone",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3019,
                    "pubMedId": 21119048,
                    "title": "CDB-4124, a progesterone receptor modulator, inhibits mammary carcinogenesis by suppressing cell proliferation and inducing apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21119048"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2387,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lonaprisan inhibited cell cycle progression of PGR and ESR1 positive human breast carcinoma cells in culture (PMID: 20043998).",
            "molecularProfile": {
                "id": 7400,
                "profileName": "ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2818,
                "therapyName": "Lonaprisan",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3020,
                    "pubMedId": 20043998,
                    "title": "In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20043998"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4269,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cixutumumab treatment had no beneficial effects on progression-free survival and overall survival in patients with hormone receptor positive (Esr1 and/or Pgr positive) breast adenocarcinoma (PMID: 26324738).",
            "molecularProfile": {
                "id": 7400,
                "profileName": "ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 701,
                "therapyName": "Cixutumumab",
                "synonyms": null
            },
            "indication": {
                "id": 3458,
                "name": "breast adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4473,
                    "pubMedId": 26324738,
                    "title": "Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17586,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Balversa (erdafitinib), Faslodex (fulvestrant), and Ibrance (palbociclib) inhibited tumor growth and resulted in complete response in 3 of 10 ESR1 (estrogen receptor alpha)-positive/ERBB2 (HER2)-negative patient-derived xenograft models with FGFR1 amplification (PMID: 30914635).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 6099,
                "therapyName": "Erdafitinib + Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17587,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a subgroup of patients from the MONALEESA-2 trial with ESR1 (ER alpha)-positive/ERBB2 (HER2)-negative breast cancer with FGFR1 amplification demonstrated a trend toward shorter progression-free survival following treatment with Kisqali (ribociclib) and Femara (letrozole) compared to patients without FGFR1 amplification (10.61 months vs. 24.84 months, p=0.075) (PMID: 30914635).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17436,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the triple combination of Lucitanib (E-3810), Faslodex (fulvestrant), and Verzenio (abemaciclib) resulted in increased growth arrest in ESR1 (ER)-positive breast cancer cells harboring FGFR1 amplification in culture, compared to treatment with Faslodex (fulvestrant) plus Verzenio (abemaciclib) (PMID: 30914635).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 8499,
                "therapyName": "Abemaciclib + Fulvestrant + Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17434,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ESR1 (ER)-positive breast cancer cell lines harboring FGFR1 amplification demonstrated decreased sensitivity to combination Faslodex (fulvestrant) plus Ibrance (palbociclib) compared to a cell line without FGFR1 amplification in culture (PMID: 30914635).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9710,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, three patients with estrogen-receptor positive breast cancer harboring an FGFR1 amplification did not demonstrate a clinical benefit when treated with the combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17433,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ESR1 (ER)-positive breast cancer cell lines harboring FGFR1 amplification demonstrated decreased sensitivity to combination Faslodex (fulvestrant) plus Kisqali (ribociclib) compared to a cell line without FGFR1 amplification in culture (PMID: 30914635).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 2316,
                "therapyName": "Fulvestrant + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16227,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, FGFR1 amplification was associated with resistance to Femara (letrozole) treatment in patients with ER-positive, ERBB2 (HER2)-negative breast cancer, with FGFR1 amplification observed in 43% (9/21) of letrozole-resistant tumors, compared to 7% (3/40) of sensitive tumors, and 10% (1/11) of intermediate tumors (resistant vs. intermediate and sensitive tumors, p=0.0011) (PMID: 28751448).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16229,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lucitanib (E-3810) and Faslodex (fulvestrant) combination treatment demonstrated improved potency compared to single drug treatment, resulted in enhanced inhibition of downstream signaling and proliferation of FGFR1-amplified, ER-positive, ERBB2 (HER2)-negative breast cancer cells in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models (PMID: 28751448).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 7952,
                "therapyName": "Fulvestrant + Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the triple combination of Lucitanib (E-3810), Faslodex (fulvestrant), and Ibrance (palbociclib) resulted in decreased growth, decreased levels of phosphorylated RB1, FRS2, and ERK1/2, and increased cell cycle arrest in ESR1 (ER)-positive breast cancer cells harboring FGFR1 amplification in culture, compared to treatment with Faslodex (fulvestrant) plus Ibrance (palbociclib) (PMID: 30914635).",
            "molecularProfile": {
                "id": 13347,
                "profileName": "ESR1 pos FGFR1 amp"
            },
            "therapy": {
                "id": 8498,
                "therapyName": "Fulvestrant + Lucitanib  + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3674,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Herceptin (trastuzumab) in combination with Perjeta (pertuzumab) and Fulvestrant, resulted in rapid and long-lasting (12 months) response in an ESR1-positive breast cancer patient with liver metastasis that harbored ERBB2 S310F and did not demonstrate ERBB2 (HER2) amplification (PMID: 26358791).",
            "molecularProfile": {
                "id": 14295,
                "profileName": "ERBB2 S310F ESR1 pos"
            },
            "therapy": {
                "id": 3290,
                "therapyName": "Fulvestrant + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3949,
                    "pubMedId": 26358791,
                    "title": "Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3854,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) resensitized ESR1-positive breast cancer cells harboring PIK3CA mutations and expressing LYN D189Y to Falsodex (fulvestrant) in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 16502,
                "profileName": "ESR1 pos LYN D189Y PIK3CA mut"
            },
            "therapy": {
                "id": 3372,
                "therapyName": "Dasatinib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of LYN D189Y conferred resistance to Falsodex (fulvestrant)-mediated growth inhibition in ESR1-positive breast cancer cells harboring PIK3CA mutations in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 16502,
                "profileName": "ESR1 pos LYN D189Y PIK3CA mut"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17073,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8404,
                "therapyName": "Exemestane + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13046,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6721,
                "therapyName": "Carboplatin + Docetaxel + Exemestane + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12956,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Femara (letrozole) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6707,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17074,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8405,
                "therapyName": "Anastrozole + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13036,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6710,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13037,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6711,
                "therapyName": "Cyclophosphamide + Doxorubicin + Letrozole + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17079,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8407,
                "therapyName": "Anastrozole + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12955,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6706,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17083,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8408,
                "therapyName": "Lapatinib + Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17078,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8406,
                "therapyName": "Exemestane + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13045,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6719,
                "therapyName": "Carboplatin + Docetaxel + Letrozole + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13039,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Aromasin (exemestane), is indicated in guidelines for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6713,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13038,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6712,
                "therapyName": "Anastrozole + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12942,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Nolvadex (tamoxifen) is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6704,
                "therapyName": "Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17084,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Aromasin (exemestane), Tykerb (lapatinib), and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8409,
                "therapyName": "Exemestane + Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12958,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6708,
                "therapyName": "Cyclophosphamide + Doxorubicin + Exemestane + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13042,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Femara (letrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6716,
                "therapyName": "Carboplatin + Docetaxel + Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13044,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6718,
                "therapyName": "Carboplatin + Docetaxel + Pertuzumab + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17072,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8403,
                "therapyName": "Letrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17092,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Nolvadex (tamoxifen) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8411,
                "therapyName": "Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17070,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Arimidex (anastrozole) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8401,
                "therapyName": "Anastrozole + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13043,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Aromasin (exemestane), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6717,
                "therapyName": "Carboplatin + Docetaxel + Exemestane + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17086,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Faslodex (fulvestrant) and Herceptin (trastuzumab) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 8410,
                "therapyName": "Fulvestrant + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13041,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Arimidex (anastrozole), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6715,
                "therapyName": "Anastrozole + Carboplatin + Docetaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17057,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab), followed by Arimidex (anastrozole), is iincluded in the guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6720,
                "therapyName": "Anastrozole + Carboplatin + Docetaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13040,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sequential therapy, Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab), followed by Nolvadex (tamoxifen), is included in guidelines as adjuvant therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 6714,
                "therapyName": "Carboplatin + Docetaxel + Tamoxifen + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17075,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Femara (letrozole) and Tykerb (lapatinib) therapy is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-positive breast cancer (NCCN.org).",
            "molecularProfile": {
                "id": 17882,
                "profileName": "ERBB2 pos ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 1497,
                "therapyName": "Lapatinib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16861,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, treatment with 300 to 400mg of Alpelisib (BYL719) plus Faslodex (fulvestrant) in patients with advanced estrogen-receptor positive breast cancer harboring a PIK3CA mutation (n=49) versus those patients with wild-type PIK3CA (n=32) resulted in a greater median progression-free survival (9.1 vs 4.7 mo) and overall response rate (29% vs 0.0%) (PMID: 30543347; NCT01219699).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14964,
                    "pubMedId": 30543347,
                    "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30543347"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14171,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (SANDPIPER) trial, Taselisib (GDC-0032) in combination with Faslodex (fulvestrant) significantly improved progression-free survival (7.4 vs 5.4 months, HR=0.70, p=0.0037) and objective response rate (28.0% vs 11.9%, p=0.0002) compared to placebo in patients with ER-positive, ERBB2 (HER2)-negative locally advanced or metastatic breast cancer harboring PIK3CA mutations (J Clin Oncol 36, 2018 (suppl; abstr LBA1006); NCT02340221).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 4567,
                "therapyName": "Fulvestrant + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11485,
                    "pubMedId": null,
                    "title": "Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.",
                    "url": "https://meetinglibrary.asco.org/record/158535/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19953,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Taselisib (GDC-0032) combined with Faslodex (fulvestrant) improved objective response rate (ORR) (20.3%, 48/236 vs 9.7%, 10/103, p=0.0202) compared to placebo in patients with ER-positive, ERBB2 (HER2)-negative breast cancer harboring PIK3CA mutations, ORR was significantly improved in patients with multiple PIK3CA mutations (30.2%, 13/43 vs 8.7%, 2/23, p=0.0493), but not in patients with single PIK3CA mutations (18.1%, 35/193 vs 10.0%, 8/80, p=0.0981) (PMID: 31699932; NCT02340221).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 4567,
                "therapyName": "Fulvestrant + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17631,
                    "pubMedId": 31699932,
                    "title": "Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699932"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5118,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Ibrance (palbociclib) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA mutations in culture and to suppress tumor growth in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3755,
                "therapyName": "AZD8835 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5843,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3956,
                "therapyName": "Palbociclib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5849,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Alvocidib (flavopiridol) worked synergistically to inhibit survival of a ER-positive breast cancer cell line harboring a PIK3CA mutation in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3961,
                "therapyName": "Alvocidib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5869,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Falsodex (fulvestrant), Ibrance (palbociclib) and Pictilisib (GDC-0941) combination treatment resulted in enhanced growth inhibition in ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3968,
                "therapyName": "Fulvestrant + Palbociclib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19566,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Faslodex (fulvestrant) and Piqray (alpelisib) is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring a PIK3CA mutation (NCCN.org).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17066,
            "approvalStatus": "FDA approved - Has Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15154,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (SOLAR-1) trial, Alpelisib (BYL719) and Faslodex (fulvestrant) combination therapy significantly improved median progression-free survival (11.0 vs 5.7 months, HR=0.65, p=0.00065), and overall response rate (36% vs 16%, p=0.0002) compared to placebo in hormone receptor-positive, Erbb2 (Her2)-negative breast cancer patients harboring PIK3CA mutations (ESMO 2018 Congress, Oct 2018, Presidential Symposium 1, abstract LBA3; NCT02437318).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12748,
                    "pubMedId": null,
                    "title": "Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial",
                    "url": "https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Alpelisib-ALP-fulvestrant-FUL-for-advanced-breast-cancer-ABC-results-of-the-Phase-3-SOLAR-1-trial"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5854,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and XAV939 worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3964,
                "therapyName": "Palbociclib + XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5855,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and PD173074 worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3965,
                "therapyName": "Palbociclib + PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5853,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Zolinza (vorinostat) worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3963,
                "therapyName": "Palbociclib + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4579,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BELLE-2), combination treatment of Buparlisib (BKM120) and Falsodex (fulvestrant) resulted in improved progression-free survival (4.7 months) in hormone receptor-positive/ERBB2 (HER2) negative breast cancer patients harboring PIK3CA mutations compared to Falsodex (fulvestrant) plus placebo treatment alone (1.6 months) (SABCS, 2016, Abstract S4-07; PMID: 26681740; NCT01610284).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1546,
                "therapyName": "Buparlisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4620,
                    "pubMedId": 26681740,
                    "title": "PI3K Inhibitor Improves PFS in BELLE-2 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26681740"
                },
                {
                    "id": 7726,
                    "pubMedId": null,
                    "title": "BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2\u2013, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment",
                    "url": "https://www.sabcs.org/Past-Meetings"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5850,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and BEZ235 worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1515,
                "therapyName": "BEZ235 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9704,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, 71% (5/7) of estrogen-receptor positive breast cancer patients that achieved a clinical benefit when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) harbored a PIK3CA mutation (PMID: 27126994).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5845,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Afinitor (everolimus) worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3958,
                "therapyName": "Everolimus + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5848,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and PF-04691502 worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3960,
                "therapyName": "Palbociclib + PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5842,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prolonged exposure to Ibrance (palbociclib) resulted in decreased cell-cycle arrest in ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5852,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and GSK2194069 worked synergistically to inhibit the survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3962,
                "therapyName": "GSK2194069 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5851,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Nolvadex (tamoxifen) worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3542,
                "therapyName": "Palbociclib + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Falsodex (fulvestrant) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA mutations in culture and to suppress tumor growth in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3753,
                "therapyName": "AZD8835 + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5844,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and MK2206 worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3957,
                "therapyName": "MK2206 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5847,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and GSK2334470 worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3959,
                "therapyName": "GSK2334470 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19384,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (POSEIDON), combination of Nolvadex (tamoxifen) and Taselisib (GDC-0032) resulted in 3 objective responses and 5 stable disease in 8 patients with ESR1-positive metastatic breast cancer harboring PIK3CA mutations, however, objective response rate (38% vs 14%) and time to progression (153 vs 113 days) were not statistically significantly different from PIK3CA wild-type group (PMID: 31439579; NCT02301988).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 9009,
                "therapyName": "Tamoxifen + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16939,
                    "pubMedId": 31439579,
                    "title": "POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31439579"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5846,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3955,
                "therapyName": "Linsitinib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17718,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (26/40, 43.3% vs 30/67, 44.8%) or pathologic complete response rate (1/60, 1.7% vs 2/67, 3.0%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA mutant breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5856,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Tanespimycin (17-AAG) worked synergistically to inhibit survival of ER-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 18593,
                "profileName": "ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 3966,
                "therapyName": "Palbociclib + Tanespimycin",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5061,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with Rapamune (sirolimus) to inhibit proliferation of ER- and HHAT-positive breast cancer cells in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3747,
                "therapyName": "RU-SKI 43 + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5060,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with LY294002 to inhibit proliferation of ESR1- and HHAT-positive breast cancer cells in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3746,
                "therapyName": "LY294002 + RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5063,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with Nolvadex (tamoxifen) to inhibit proliferation of ER- and HHAT-positive breast cancer cells in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3748,
                "therapyName": "RU-SKI 43 + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5056,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 inhibited proliferation of breast cancer cells positive for ESR1 and HHAT in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3744,
                "therapyName": "RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5116,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835, Falsodex (fulvestrant), and Ibrance (palbociclib) combination treatment resulted in profound tumor regression in xenograft models of estrogen receptor (ER)-positive breast cancer harboring PIK3CA E545K (PMID: 26839307).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 3754,
                "therapyName": "AZD8835 + Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9693,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, 100% (3/3) of estrogen-receptor positive breast cancer patients harboring PIK3CA E545K did not demonstrate a clinical benefit when treated with the combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5119,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Ibrance (palbociclib) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA E545K in culture and to suppress tumor growth in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 3755,
                "therapyName": "AZD8835 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8365,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of Faslodex (fulvestrant) and Pictilisib (GDC-0941) resulted in increased apoptotic activity, tumor regression, and decreased PI3K signaling in Faslodex (fulvestrant)-resistant estrogen receptor (ER) positive breast cancer cell line xenograft models harboring PIK3CA E545K (PMID: 26733612).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 4357,
                "therapyName": "Fulvestrant + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6631,
                    "pubMedId": 26733612,
                    "title": "Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17130,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8361,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an estrogen-receptor (ER) positive breast cancer cell line harboring PIK3CA E545K demonstrated sensitivity to treatment with Faslodex (fulvestrant) in culture, resulting in cell growth inhibition (PMID: 26733612).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6631,
                    "pubMedId": 26733612,
                    "title": "Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8360,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an estrogen-receptor (ER) positive breast cancer cell line harboring PIK3CA E545K demonstrated sensitivity to treatment with Pictilisib (GDC-0941) in culture, resulting in decreased cell viability (PMID: 26733612).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6631,
                    "pubMedId": 26733612,
                    "title": "Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5114,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Falsodex (fulvestrant) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA E545K in culture and to suppress tumor growth in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 20267,
                "profileName": "ESR1 pos PIK3CA E545K"
            },
            "therapy": {
                "id": 3753,
                "therapyName": "AZD8835 + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5120,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Ibrance (palbociclib) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and to induce tumor regression in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 20268,
                "profileName": "ESR1 pos PIK3CA K111N"
            },
            "therapy": {
                "id": 3755,
                "therapyName": "AZD8835 + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8835 and Falsodex (fulvestrant) worked synergistically to inhibit proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and to induce tumor regression in xenograft models (PMID: 26839307).",
            "molecularProfile": {
                "id": 20268,
                "profileName": "ESR1 pos PIK3CA K111N"
            },
            "therapy": {
                "id": 3753,
                "therapyName": "AZD8835 + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9692,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, 80% (4/5) of estrogen-receptor positive breast cancer patients harboring PIK3CA H1047R demonstrated a clinical response, including either partial response or stable disease, when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 20269,
                "profileName": "ESR1 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8368,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Faslodex (fulvestrant) and Pictilisib (GDC-0941) resulted in tumor regression in estrogen-receptor (ER) positive breast cancer cell line xenograft models harboring PIK3CA H1047R (PMID: 26733612).",
            "molecularProfile": {
                "id": 20269,
                "profileName": "ESR1 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 4357,
                "therapyName": "Fulvestrant + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6631,
                    "pubMedId": 26733612,
                    "title": "Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26733612"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17134,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 20269,
                "profileName": "ESR1 pos PIK3CA H1047R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5527,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Seribantumab (MM-12) and Femara (letrozole) inhibited ERBB3 (HER3) activation and tumor growth and delayed onset of resistance to Femara (letrozole) in estrogen receptor (ER)-positive breast cancer xenograft models, and overcame resistance in Femara (letrozole)-resistant models (PMID: 26310543).",
            "molecularProfile": {
                "id": 20964,
                "profileName": "ERBB3 pos ESR1 pos"
            },
            "therapy": {
                "id": 3878,
                "therapyName": "Letrozole + Seribantumab",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5081,
                    "pubMedId": 26310543,
                    "title": "Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26310543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5528,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Afinitor (everolimus) and Femara inhibited tumor growth in Femara (letrozole)-resistant ESR1-positive breast cancer cell line xenograft models (PMID: 26310543).",
            "molecularProfile": {
                "id": 20964,
                "profileName": "ERBB3 pos ESR1 pos"
            },
            "therapy": {
                "id": 1621,
                "therapyName": "Everolimus + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5081,
                    "pubMedId": 26310543,
                    "title": "Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26310543"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5858,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit the survival of ER-positive, PTEN-null breast cancer cell lines in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 21949,
                "profileName": "ESR1 pos PTEN loss"
            },
            "therapy": {
                "id": 3956,
                "therapyName": "Palbociclib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10285,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer xenograft model expressing ESR1 and harboring loss of PTEN was sensitive to Miransertib (ARQ092), demonstrating inhibition of tumor growth (PMID: 26469692).",
            "molecularProfile": {
                "id": 21949,
                "profileName": "ESR1 pos PTEN loss"
            },
            "therapy": {
                "id": 635,
                "therapyName": "Miransertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5860,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in PIK3CA wild-type, ER-positive breast cancer cell lines in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 21969,
                "profileName": "ESR1 pos PIK3CA wild-type"
            },
            "therapy": {
                "id": 3956,
                "therapyName": "Palbociclib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17723,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NEO-ORB), Piqray (Alpelisib) and Femara (letrozole) combination treatment in the neoadjuvant setteing did not improve objective response rate (45/71, 63.4% vs 36/59, 61.0%) or pathologic complete response rate (2/71, 2.8% vs 1/59, 1.7%) compared to Femara (letrozole) plus placebo in patients with hormone receptor-positive, ERBB2 (HER2)-negative, PIK3CA wild-type breast cancer (PMID: 30723140; NCT01923168).",
            "molecularProfile": {
                "id": 21969,
                "profileName": "ESR1 pos PIK3CA wild-type"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15751,
                    "pubMedId": 30723140,
                    "title": "A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30723140"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5868,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDK2 knockdown with siRNA sensitized ER-positive breast cancer cells harboring PIK3CA mutations to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 21973,
                "profileName": "CDK2 dec exp ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18295,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-1/TRIO-18), CCND1 amplification and/or CDKN2A loss did not correlate with response to addition of Ibrance (palbociclib) to Femara (letrozole) in patients with estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.37 and 0.19 (p=0.13) in patients with or without CCND1 amplification and/or CDKN2A loss, respectively (PMID: 25524798; NCT00721409).",
            "molecularProfile": {
                "id": 21974,
                "profileName": "CCND1 amp ESR1 pos"
            },
            "therapy": {
                "id": 2922,
                "therapyName": "Letrozole + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16122,
                    "pubMedId": 25524798,
                    "title": "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25524798"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5870,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Kisqali (ribociclib) combination treatment resulted in growth inhibition and tumor regression in patient-derived xenograft (PDX) models of ER-positive, CCND1 amplified breast cancer (PMID: 27020857).",
            "molecularProfile": {
                "id": 21974,
                "profileName": "CCND1 amp ESR1 pos"
            },
            "therapy": {
                "id": 3969,
                "therapyName": "Alpelisib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7139,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with LY3039478 resulted in partial response in one patient with ER-positive, PR-positive, ERBB2 (HER2)-negative breast cancer (J Clin Oncol 33, 2015 (suppl; abstr 2533)).",
            "molecularProfile": {
                "id": 24496,
                "profileName": "ERBB2 neg ESR1 pos PGR pos"
            },
            "therapy": {
                "id": 2958,
                "therapyName": "LY3039478",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5879,
                    "pubMedId": null,
                    "title": "First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer",
                    "url": "http://meetinglibrary.asco.org/content/144588-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7398,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD5363 and Arimidex (anastrozole) acted synergistically to inhibit proliferation of estrogen receptor (ESR1)-positive cell lines harboring PIK3CA activating mutations in culture (PMID: 26116361).",
            "molecularProfile": {
                "id": 25360,
                "profileName": "ESR1 pos PIK3CA act mut"
            },
            "therapy": {
                "id": 4490,
                "therapyName": "Anastrozole + Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6340,
                    "pubMedId": 26116361,
                    "title": "AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7387,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD5363 and Falsodex (fulvestrant) worked synergistically to inhibit proliferation of several endocrine-sensitive and resistant estrogen receptor (ESR1)-positive breast cancer cell lines in culture, including cell lines with PIK3CA activating mutations (PMID: 26116361).",
            "molecularProfile": {
                "id": 25360,
                "profileName": "ESR1 pos PIK3CA act mut"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6340,
                    "pubMedId": 26116361,
                    "title": "AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7389,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the AZD5363 inhibited proliferation of several endocrine-sensitive and resistant estrogen receptor (ESR1)-positive breast cancer cell lines in culture, including a cell line with PTEN inactivation (PMID: 26116361).",
            "molecularProfile": {
                "id": 25362,
                "profileName": "ESR1 pos PTEN inact mut"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6340,
                    "pubMedId": 26116361,
                    "title": "AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26116361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9424,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ER-positive ovarian serous carcinoma cells with high Mapk1 activity were resistant to Selumetinib (AZD6244) in culture (PMID: 26482043).",
            "molecularProfile": {
                "id": 26842,
                "profileName": "ESR1 pos MAPK1 pos"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7184,
                    "pubMedId": 26482043,
                    "title": "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482043"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9423,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) and Selumetinib (AZD6244) synergistically inhibited survival of ER-positive ovarian serous carcinoma cells with high Mapk1 activity in culture (PMID: 26482043).",
            "molecularProfile": {
                "id": 26842,
                "profileName": "ESR1 pos MAPK1 pos"
            },
            "therapy": {
                "id": 5015,
                "therapyName": "Fulvestrant + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 50933,
                "name": "ovarian serous carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7184,
                    "pubMedId": 26482043,
                    "title": "MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482043"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14948,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with RAD140 inhibited proliferation of AR/ESR1-positive breast cancer cells in culture and blocked tumor growth in AR/ESR1-positive breast cancer patient-derived xenograft (PDX) models (PMID: 28974548).",
            "molecularProfile": {
                "id": 26899,
                "profileName": "AR pos ESR1 pos"
            },
            "therapy": {
                "id": 7211,
                "therapyName": "RAD140",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11832,
                    "pubMedId": 28974548,
                    "title": "Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28974548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14949,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and RAD140 resulted in enhanced antitumor efficacy in AR/ESR1-positive breast cancer patient-derived xenograft (PDX) models compared to either agent alone (PMID: 28974548).",
            "molecularProfile": {
                "id": 26899,
                "profileName": "AR pos ESR1 pos"
            },
            "therapy": {
                "id": 7216,
                "therapyName": "Palbociclib + RAD140",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11832,
                    "pubMedId": 28974548,
                    "title": "Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28974548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Afimoxifene (4-hydroxy-tamoxifen) and XMU-MP-2 demonstrated synergy in inhibiting growth of a breast cancer cell line with ESR1 (ER) and PTK6 expression in culture (PMID: 27758886).",
            "molecularProfile": {
                "id": 26973,
                "profileName": "ESR1 pos PTK6 pos"
            },
            "therapy": {
                "id": 5158,
                "therapyName": "Afimoxifene + XMU-MP-2",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7466,
                    "pubMedId": 27758886,
                    "title": "Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9694,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA Q546K demonstrated stable disease when treated with the combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26980,
                "profileName": "ESR1 pos PIK3CA Q546K"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9695,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA Q546P demonstrated progressive disease when treated with the combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26981,
                "profileName": "ESR1 pos PIK3CA Q546P"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9697,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA P447_L455del demonstrated a partial response when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26983,
                "profileName": "ESR1 pos PIK3CA P447_L455del"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9699,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA I273V and PIK3CA E545K demonstrated a partial response when treated with the combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26986,
                "profileName": "ESR1 pos PIK3CA I273V PIK3CA E545K"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9700,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA C420R demonstrated stable disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26988,
                "profileName": "ESR1 pos PIK3CA C420R"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17125,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA C420R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 26988,
                "profileName": "ESR1 pos PIK3CA C420R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17126,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E542K (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 26989,
                "profileName": "ESR1 pos PIK3CA E542K"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9702,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA E542K demonstrated progressive disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26989,
                "profileName": "ESR1 pos PIK3CA E542K"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10949,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (SUMMIT), Nerlynx (neratinib) and Faslodex (fulvestrant) combination treatment resulted in an overall response rate of 29.8% (14/47; 4 complete responses, 10 partial responses), a median progression-free survival of 5.4 months, and median duration of response of 9.2 months in patients with ESR1-positive, ERBB2 (HER2)-mutant metastatic breast cancer (PMID: 31806627; NCT01953926).",
            "molecularProfile": {
                "id": 27861,
                "profileName": "ERBB2 mut ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8951,
                    "pubMedId": null,
                    "title": "Neratinib + fulvestrant in ERBB2-mutant, HER2\u2013non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial",
                    "url": "http://cancerres.aacrjournals.org/content/77/4_Supplement/PD2-08.short"
                },
                {
                    "id": 17785,
                    "pubMedId": 31806627,
                    "title": "Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31806627"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11104,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Abemaciclib (LY2835219) and Faslodex (fulvestrant) combination therapy resulted in improved median progression free survival (16.4 vs 9.3 months) and overall response rate (48.1% vs 21.3%) compared to placebo in patients with treatment refractory hormone receptor positive, Erbb2 (Her2) negative breast cancer (PMID: 28580882).",
            "molecularProfile": {
                "id": 27929,
                "profileName": "ERBB2 neg ESR1 pos"
            },
            "therapy": {
                "id": 5859,
                "therapyName": "Abemaciclib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9173,
                    "pubMedId": 28580882,
                    "title": "MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28580882"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2660,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, strongly ESR1 (ER)-positive patients with ERBB2 (HER2)-negative breast cancer had a decreased response to the combination of Avastin (bevacizumab), docetaxel, fluorouracil, epirubicin, and cyclophosphamide compared to ESR1-negative and weakly positive patients, with complete response (CR) in 6% (14/232) compared to an overall CR of 22% (87/388) (PMID: 25975632).",
            "molecularProfile": {
                "id": 27929,
                "profileName": "ERBB2 neg ESR1 pos"
            },
            "therapy": {
                "id": 2988,
                "therapyName": "Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3374,
                    "pubMedId": 25975632,
                    "title": "Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25975632"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12381,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of MK2206 to Arimidex (anastrozole) treatment did not further induce apoptosis and resulted in no pathologic complete response (0/13) in estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer patients harboring PIK3CA mutations (PMID: 28874413; NCT01776008).",
            "molecularProfile": {
                "id": 28721,
                "profileName": "ERBB2 neg ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 4188,
                "therapyName": "Anastrozole + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10361,
                    "pubMedId": 28874413,
                    "title": "A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28874413"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of LYN E159K in ESR1-positive breast cancer cells resulted in decreased response to Faslodex (fulvestrant)-induced growth inhibition in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 28760,
                "profileName": "ESR1 pos LYN E159K"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12583,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of LYN K209N in ESR1-positive breast cancer cells resulted in decreased response to Faslodex (fulvestrant)-induced growth inhibition in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 28761,
                "profileName": "ESR1 pos LYN K209N"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of LYN E159K in ESR1-positive breast cancer cells harboring PIK3CA mutations resulted in decreased response to Buparlisib (BKM120)-induced growth inhibition in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 28763,
                "profileName": "ESR1 pos LYN E159K PIK3CA mut"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12584,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of LYN K209N in ESR1-positive breast cancer cells harboring PIK3CA mutations resulted in decreased response to Buparlisib (BKM120)-induced growth inhibition in culture (PMID: 25401474).",
            "molecularProfile": {
                "id": 28764,
                "profileName": "ESR1 pos LYN K209N PIK3CA mut"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4205,
                    "pubMedId": 25401474,
                    "title": "LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25401474"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17498,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in guidelines as second line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients who have progressed on first line therapy (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17489,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with chemotherapy or endocrine therapy is included in guidelines as first line therapy for advanced ERBB2 (HER2)-positive, ESR1-positive breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17494,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tykerb (lapatinib) combined with endocrine therapy is included in guidelines as first-line therapy or maintenance therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17492,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with chemotherapy or endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2019,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with the combination of Tykerb (lapatinib) and Femara (letrozole) resulted in an improved median progression-free survival of 8.2 months compared to 3.0 months with Femara (letrozole) plus placebo in patients with hormone receptor-positive metastatic breast cancer that is also ERBB2 (HER2)-positive (defined as FISH positive, IHC 3+, or FISH pos and IHC 2+) (PMID: 19786658; NCT00073528).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 1497,
                "therapyName": "Lapatinib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2500,
                    "pubMedId": 19786658,
                    "title": "Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19786658"
                },
                {
                    "id": 15539,
                    "pubMedId": null,
                    "title": "Tykerb (lapatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17496,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tykerb (lapatinib) and Herceptin (trastuzumab) with endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 28936,
                "profileName": "ERBB2 over exp ESR1 pos"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15764,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15753,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15749,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15810,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15745,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15862,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15848,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15837,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) S653C in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31189,
                "profileName": "ERBB2 S653C ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15979,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture, resulting in growth inhibition (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15849,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15976,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture, resulting in growth inhibition (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15886,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15980,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5015,
                "therapyName": "Fulvestrant + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15827,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15750,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15804,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an estrogen-receptor (ESR1)-positive cell line harboring ERBB2 (HER2) L755S demonstrated resistance to Faslodex (fulvestrant) in culture, and treatment with Faslodex (fulvestrant) prevented tumor growth, but did not induce regression in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15838,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15974,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical study, treatment with the combination of Nerlynx (neratinib) and Faslodex (fulvestrant) inhibited growth and reduced invasive behavior of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) L755S in culture, to a greater degree than either agent alone, and resulted in tumor regression in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15765,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15754,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L755S demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31190,
                "profileName": "ERBB2 L755S ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15981,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5015,
                "therapyName": "Fulvestrant + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15747,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15864,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15887,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15977,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture resulting in growth inhibition, and the combination of Afinitor (everolimus) and Faslodex (fulvestrant) inhibited tumor growth in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15850,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15982,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Nerlynx (neratinib), Afinitor (everolimus), and Faslodex (fulvestrant) induced nearly complete tumor regression in xenograft models of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 7842,
                "therapyName": "Everolimus + Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15840,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15755,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15978,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture resulting in growth inhibition, and the combination of Alpelisib (BYL719) and Faslodex (fulvestrant) inhibited tumor growth in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15751,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) V777L demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15805,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an estrogen-receptor (ESR1)-positive cell line harboring ERBB2 (HER2) V777L demonstrated resistance to Faslodex (fulvestrant) in culture, and treatment with Faslodex (fulvestrant) resulted in tumor growth arrest, but not regression, in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15973,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical study, treatment with the combination of Nerlynx (neratinib) and Faslodex (fulvestrant) inhibited growth and reduced invasive behavior of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) V777L in culture, to a greater degree than either agent alone, and resulted in tumor regression in xenograft models (PMID: 30314968).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15766,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor (ESR1)-positive breast cancer cells expressing ERBB2 (HER2) V777L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31191,
                "profileName": "ERBB2 V777L ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15972,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) therapy resulted in clinical response in a patient with estrogen-receptor (ESR1)-positive breast cancer harboring ERBB2 (HER2) L869R (PMID: 30314968).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15752,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15756,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15971,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, the addition of Faslodex (fulvestrant) to therapy with Nerlynx (neratinib) following progression on Nerlynx (neratinib) therapy resulted in prolonged tumor regression in a patient with estrogen-receptor (ESR1)-positive breast cancer harboring ERBB2 (HER2) L869R (PMID: 30314968).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15767,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15748,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15888,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) L869R in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31192,
                "profileName": "ERBB2 L869R ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15891,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15884,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15861,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15807,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R143G demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31225,
                "profileName": "ERBB2 R143G ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15852,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15895,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15889,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15808,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) P1074L were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31226,
                "profileName": "ERBB2 P1074L ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Capivasertib (AZD5363) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 4452,
                "therapyName": "Capivasertib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15853,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of VX-11e did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 7755,
                "therapyName": "Fulvestrant + VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L demonstrated resistance when treated with Faslodex (fulvestrant) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15890,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Afinitor (everolimus) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 1589,
                "therapyName": "Everolimus + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15846,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 7754,
                "therapyName": "Fulvestrant + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15809,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L were resistant to the combination therapy of Faslodex (fulvestrant) and Ibrance (palbociclib) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15902,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L demonstrated resistance when treated with GDC-0810 in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 2150,
                "therapyName": "GDC-0810",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15893,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Nerlynx (neratinib) results in restored sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 5705,
                "therapyName": "Fulvestrant + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15860,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Alpelisib (BYL719) did not restore sensitivity to Faslodex (fulvestrant) in estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15896,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, estrogen-receptor positive breast cancer cells expressing ERBB2 (HER2) R1153L demonstrated resistance when treated with Nolvadex (tamoxifen) in culture (PMID: 30531871).",
            "molecularProfile": {
                "id": 31234,
                "profileName": "ERBB2 R1153L ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13733,
                    "pubMedId": 30531871,
                    "title": "Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30531871"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15975,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Faslodex (fulvestrant) inhibited growth of estrogen-receptor (ESR1)-positive breast cancer cells harboring ERBB2 (HER2) G309A in culture (PMID: 30314968).",
            "molecularProfile": {
                "id": 31352,
                "profileName": "ERBB2 G309A ESR1 pos"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13816,
                    "pubMedId": 30314968,
                    "title": "Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30314968"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16228,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, FGF3, FGF4, and FGF19 were coamplified in 90% (8/9) of FGFR1-amplified tumors in patients with ER-positive, ERBB2 (HER2)-negative breast cancer, and the coamplification was associated with resistance to Femara (letrozole) treatment (p=0.0001) (PMID: 28751448).",
            "molecularProfile": {
                "id": 31564,
                "profileName": "ESR1 pos FGF19 amp FGF3 amp FGF4 amp FGFR1 amp"
            },
            "therapy": {
                "id": 794,
                "therapyName": "Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14363,
                    "pubMedId": 28751448,
                    "title": "Association of FGFR1 with ER\u03b1 Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28751448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16417,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Nolvadex (tamoxifen) and Venclexta (venetoclax) combination treatment resulted in an objective response rate of 45% (15/33, 1 complete response, 14 partial response) and a clinical benefit rate of 70% (23/33) in patients with ER, BCL2-positive, ERBB2 (HER2)-nonamplified (negative) metastatic breast cancer, with a median duration of response of 42 weeks (PMID: 30518523).",
            "molecularProfile": {
                "id": 31628,
                "profileName": "BCL2 pos ESR1 pos"
            },
            "therapy": {
                "id": 8024,
                "therapyName": "Tamoxifen + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14490,
                    "pubMedId": 30518523,
                    "title": "A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518523"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17432,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Lucitanib (E-3810) to combination Faslodex (fulvestrant) plus Ibrance (palbociclib) overcame resistance conferred by FGFR1 overexpression in ESR1 (ER)-positive breast cancer cells in culture, and resulted in decreased tumor growth and RB1 phosphorylation compared to Faslodex (fulvestrant) plus Ibrance (palbociclib) in FGFR1-overexpressing ER (ESR1)-positive breast cancer cell line xenograft models (PMID: 30914635).",
            "molecularProfile": {
                "id": 32600,
                "profileName": "ESR1 pos FGFR1 over exp"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17431,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of FGFR1 conferred resistance to treatment with the combination of (fulvestrant) and Ibrance (palbociclib in ESR1 (ER)-positive breast cancer cells, in culture and in xenograft models (PMID: 30914635).",
            "molecularProfile": {
                "id": 32600,
                "profileName": "ESR1 pos FGFR1 over exp"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15486,
                    "pubMedId": 30914635,
                    "title": "Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30914635"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17490,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Herceptin (trastuzumab) and Perjeta (pertuzumab) with chemotherapy or endocrine therapy is included in guidelines as first line therapy for advanced ERBB2 (HER2)-positive, ESR1-positive breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17497,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kadcyla (ado-trastuzumab emtansine) is included in guidelines as second line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients who have progressed on first line therapy (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 1402,
                "therapyName": "Ado-trastuzumab emtansine",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17491,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Herceptin (trastuzumab) combined with chemotherapy or endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17493,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tykerb (lapatinib) combined with endocrine therapy is included in guidelines as first-line therapy or maintenance therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17495,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tykerb (lapatinib) and Herceptin (trastuzumab) with endocrine therapy is included in guidelines as first line therapy for ERBB2 (HER2)-positive, ESR1-positive advanced breast cancer patients (PMID: 30032243; ESMO.org).",
            "molecularProfile": {
                "id": 32622,
                "profileName": "ERBB2 amp ESR1 pos"
            },
            "therapy": {
                "id": 1414,
                "therapyName": "Lapatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15503,
                    "pubMedId": 30032243,
                    "title": "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)\u2020.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30032243"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18276,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCND1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.471 and 0.594 (p=0.503) in CCND1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33094,
                "profileName": "CCND1 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18278,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK4 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.509 and 0.562 (p=0.627) in CDK4 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33096,
                "profileName": "CDK4 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18280,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDK6 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.605 and 0.483 (p=0.515) in CDK6 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33098,
                "profileName": "CDK6 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18282,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), RB1 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.425 and 0.672 (p=0.123) in RB1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33100,
                "profileName": "ESR1 pos RB1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18289,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE1 expression level negatively correlates with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.320 and 0.851 (p=0.00238) in CCNE1 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33102,
                "profileName": "CCNE1 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18284,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CDKN2A expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.504 and 0.555 (p=0.730) in CDKN2A low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33112,
                "profileName": "CDKN2A pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18286,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PALOMA-3), CCNE2 expression level did not correlate with response to addition of Ibrance (palbociclib) to Faslodex (fulvestrant) in patients with hormone receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.513 and 0.560 (p=0.834) in CCNE2 low and high expression groups, respectively (PMID: 30807234; NCT01942135).",
            "molecularProfile": {
                "id": 33115,
                "profileName": "CCNE2 pos ESR1 pos"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16119,
                    "pubMedId": 30807234,
                    "title": "Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30807234"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18296,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PALOMA-1/TRIO-18), CCND1 amplification and/or CDKN2A loss did not correlate with response to addition of Ibrance (palbociclib) to Femara (letrozole) in patients with estrogen receptor-positive, Erbb2 (Her2)-negative breast cancer, with hazard ratios for progression-free survival of Ibrance (palbociclib) versus placebo of 0.37 and 0.19 (p=0.13) in patients with or without CCND1 amplification and/or CDKN2A loss, respectively (PMID: 25524798; NCT00721409).",
            "molecularProfile": {
                "id": 33130,
                "profileName": "CDKN2A loss ESR1 pos"
            },
            "therapy": {
                "id": 2922,
                "therapyName": "Letrozole + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16122,
                    "pubMedId": 25524798,
                    "title": "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25524798"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18810,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Faslodex (fulvestrant) and Piqray (alpelisib) is included in guidelines as systemic therapy for patients with hormone receptor-positive (ER and/or PR), ERBB2 (HER2)-negative breast cancer harboring a PIK3CA mutation (NCCN.org).",
            "molecularProfile": {
                "id": 33604,
                "profileName": "ESR1 pos PGR pos PIK3CA mut"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17127,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545A (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34221,
                "profileName": "ESR1 pos PIK3CA E545A"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17128,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545D (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34222,
                "profileName": "ESR1 pos PIK3CA E545D"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17129,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA E545G (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34223,
                "profileName": "ESR1 pos PIK3CA E545G"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17131,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546R (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34224,
                "profileName": "ESR1 pos PIK3CA Q546R"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17132,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA Q546E (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34225,
                "profileName": "ESR1 pos PIK3CA Q546E"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17133,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047L (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34226,
                "profileName": "ESR1 pos PIK3CA H1047L"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17135,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047Y (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34227,
                "profileName": "ESR1 pos PIK3CA H1047Y"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1417,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, low p27 (CDKN1B) expression was associated with Nolvadex (tamoxifen) resistance in premenopausal ER or ER/PR-positive breast cancer patients, while patients with high p27 (CDKN1B) expression benefited from Nolvadex (tamoxifen) treatment (PMID: 21351264).",
            "molecularProfile": {
                "id": 34248,
                "profileName": "CDKN1B dec exp ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 1205,
                    "pubMedId": 21351264,
                    "title": "p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21351264"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1418,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, low p27 (CDKN1B) expression was associated with Nolvadex (tamoxifen) resistance in premenopausal ER or ER/PR-positive breast cancer patients, while patients with high p27 (CDKN1B) expression benefited from Nolvadex (tamoxifen) treatment (PMID: 21351264).",
            "molecularProfile": {
                "id": 34249,
                "profileName": "CDKN1B over exp ESR1 pos"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1205,
                    "pubMedId": 21351264,
                    "title": "p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21351264"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20269,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of NF1 with siRNA or shRNA led to decrease Nf1 protein expression and resistance to Faslodex (fulvestrant) treatment in Esr1-positive breast cancer cell lines in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 744,
                "therapyName": "Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20272,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Nolvadex (tamoxifen) synergistically inhibited growth of Esr1-positive breast cancer cells with knocked down Nf1 expression by siRNA in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 3542,
                "therapyName": "Palbociclib + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20270,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of NF1 with siRNA or shRNA led to decrease Nf1 protein expression and resistance to Nolvadex (tamoxifen) treatment in Esr1-positive breast cancer cell lines in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 1456,
                "therapyName": "Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20273,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Faslodex (fulvestrant) synergistically inhibited growth of Esr1-positive breast cancer cells with knocked down Nf1 expression by siRNA in culture (PMID: 31591187).",
            "molecularProfile": {
                "id": 34993,
                "profileName": "ESR1 pos NF1 dec exp"
            },
            "therapy": {
                "id": 3205,
                "therapyName": "Fulvestrant + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17788,
                    "pubMedId": 31591187,
                    "title": "Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591187"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1188,
            "profileName": "ESR1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2349,
            "profileName": "ESR1 pos EZH2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7400,
            "profileName": "ESR1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13347,
            "profileName": "ESR1 pos FGFR1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13348,
            "profileName": "ESR1 pos FGFR1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14067,
            "profileName": "AKT1 E17K ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14295,
            "profileName": "ERBB2 S310F ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16502,
            "profileName": "ESR1 pos LYN D189Y PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17882,
            "profileName": "ERBB2 pos ESR1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17883,
            "profileName": "ERBB2 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18593,
            "profileName": "ESR1 pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20218,
            "profileName": "ESR1 pos HHAT pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20267,
            "profileName": "ESR1 pos PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20268,
            "profileName": "ESR1 pos PIK3CA K111N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20269,
            "profileName": "ESR1 pos PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20964,
            "profileName": "ERBB3 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21949,
            "profileName": "ESR1 pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21969,
            "profileName": "ESR1 pos PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21973,
            "profileName": "CDK2 dec exp ESR1 pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21974,
            "profileName": "CCND1 amp ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24496,
            "profileName": "ERBB2 neg ESR1 pos PGR pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25360,
            "profileName": "ESR1 pos PIK3CA act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25362,
            "profileName": "ESR1 pos PTEN inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26842,
            "profileName": "ESR1 pos MAPK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26899,
            "profileName": "AR pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26900,
            "profileName": "CCND1 pos ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26908,
            "profileName": "AR pos ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26973,
            "profileName": "ESR1 pos PTK6 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26980,
            "profileName": "ESR1 pos PIK3CA Q546K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26981,
            "profileName": "ESR1 pos PIK3CA Q546P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26983,
            "profileName": "ESR1 pos PIK3CA P447_L455del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26986,
            "profileName": "ESR1 pos PIK3CA I273V PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26988,
            "profileName": "ESR1 pos PIK3CA C420R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26989,
            "profileName": "ESR1 pos PIK3CA E542K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27861,
            "profileName": "ERBB2 mut ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27929,
            "profileName": "ERBB2 neg ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28721,
            "profileName": "ERBB2 neg ESR1 pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28760,
            "profileName": "ESR1 pos LYN E159K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28761,
            "profileName": "ESR1 pos LYN K209N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28763,
            "profileName": "ESR1 pos LYN E159K PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28764,
            "profileName": "ESR1 pos LYN K209N PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28936,
            "profileName": "ERBB2 over exp ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31189,
            "profileName": "ERBB2 S653C ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31190,
            "profileName": "ERBB2 L755S ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31191,
            "profileName": "ERBB2 V777L ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31192,
            "profileName": "ERBB2 L869R ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31225,
            "profileName": "ERBB2 R143G ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31226,
            "profileName": "ERBB2 P1074L ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31228,
            "profileName": "ERBB2 neg ESR1 pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31230,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31231,
            "profileName": "ERBB2 neg ESR1 pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31233,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31234,
            "profileName": "ERBB2 R1153L ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31235,
            "profileName": "ERBB2 neg ESR1 pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31237,
            "profileName": "ERBB2 neg ESR1 pos PGR pos PTEN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31352,
            "profileName": "ERBB2 G309A ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31564,
            "profileName": "ESR1 pos FGF19 amp FGF3 amp FGF4 amp FGFR1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31628,
            "profileName": "BCL2 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32600,
            "profileName": "ESR1 pos FGFR1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32622,
            "profileName": "ERBB2 amp ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33094,
            "profileName": "CCND1 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33096,
            "profileName": "CDK4 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33098,
            "profileName": "CDK6 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33100,
            "profileName": "ESR1 pos RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33102,
            "profileName": "CCNE1 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33112,
            "profileName": "CDKN2A pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33115,
            "profileName": "CCNE2 pos ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33130,
            "profileName": "CDKN2A loss ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33604,
            "profileName": "ESR1 pos PGR pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34221,
            "profileName": "ESR1 pos PIK3CA E545A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34222,
            "profileName": "ESR1 pos PIK3CA E545D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34223,
            "profileName": "ESR1 pos PIK3CA E545G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34224,
            "profileName": "ESR1 pos PIK3CA Q546R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34225,
            "profileName": "ESR1 pos PIK3CA Q546E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34226,
            "profileName": "ESR1 pos PIK3CA H1047L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34227,
            "profileName": "ESR1 pos PIK3CA H1047Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34248,
            "profileName": "CDKN1B dec exp ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34249,
            "profileName": "CDKN1B over exp ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34986,
            "profileName": "ERBB2 V697L ERBB2 amp ESR1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34993,
            "profileName": "ESR1 pos NF1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}